Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Refractory Multiple Myeloma Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Proteosome Inhibitor
1.2.3 Immunomodulators
1.2.4 Anti-CD38 Monoclonal Antibody
1.2.5 Others
1.3 Market by Application
1.3.1 Global Refractory Multiple Myeloma Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Hospital
1.3.3 Specialty Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Refractory Multiple Myeloma Market Perspective (2018-2033)
2.2 Refractory Multiple Myeloma Growth Trends by Region
2.2.1 Global Refractory Multiple Myeloma Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Refractory Multiple Myeloma Historic Market Size by Region (2018-2023)
2.2.3 Refractory Multiple Myeloma Forecasted Market Size by Region (2024-2033)
2.3 Refractory Multiple Myeloma Market Dynamics
2.3.1 Refractory Multiple Myeloma Industry Trends
2.3.2 Refractory Multiple Myeloma Market Drivers
2.3.3 Refractory Multiple Myeloma Market Challenges
2.3.4 Refractory Multiple Myeloma Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Refractory Multiple Myeloma Players by Revenue
3.1.1 Global Top Refractory Multiple Myeloma Players by Revenue (2018-2023)
3.1.2 Global Refractory Multiple Myeloma Revenue Market Share by Players (2018-2023)
3.2 Global Refractory Multiple Myeloma Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Refractory Multiple Myeloma Revenue
3.4 Global Refractory Multiple Myeloma Market Concentration Ratio
3.4.1 Global Refractory Multiple Myeloma Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Refractory Multiple Myeloma Revenue in 2022
3.5 Refractory Multiple Myeloma Key Players Head office and Area Served
3.6 Key Players Refractory Multiple Myeloma Product Solution and Service
3.7 Date of Enter into Refractory Multiple Myeloma Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Refractory Multiple Myeloma Breakdown Data by Type
4.1 Global Refractory Multiple Myeloma Historic Market Size by Type (2018-2023)
4.2 Global Refractory Multiple Myeloma Forecasted Market Size by Type (2024-2033)
5 Refractory Multiple Myeloma Breakdown Data by Application
5.1 Global Refractory Multiple Myeloma Historic Market Size by Application (2018-2023)
5.2 Global Refractory Multiple Myeloma Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Refractory Multiple Myeloma Market Size (2018-2033)
6.2 North America Refractory Multiple Myeloma Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Refractory Multiple Myeloma Market Size by Country (2018-2023)
6.4 North America Refractory Multiple Myeloma Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Refractory Multiple Myeloma Market Size (2018-2033)
7.2 Europe Refractory Multiple Myeloma Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Refractory Multiple Myeloma Market Size by Country (2018-2023)
7.4 Europe Refractory Multiple Myeloma Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Refractory Multiple Myeloma Market Size (2018-2033)
8.2 Asia-Pacific Refractory Multiple Myeloma Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Refractory Multiple Myeloma Market Size by Region (2018-2023)
8.4 Asia-Pacific Refractory Multiple Myeloma Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Refractory Multiple Myeloma Market Size (2018-2033)
9.2 Latin America Refractory Multiple Myeloma Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Refractory Multiple Myeloma Market Size by Country (2018-2023)
9.4 Latin America Refractory Multiple Myeloma Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Refractory Multiple Myeloma Market Size (2018-2033)
10.2 Middle East & Africa Refractory Multiple Myeloma Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Refractory Multiple Myeloma Market Size by Country (2018-2023)
10.4 Middle East & Africa Refractory Multiple Myeloma Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bristol Myers Squibb
11.1.1 Bristol Myers Squibb Company Detail
11.1.2 Bristol Myers Squibb Business Overview
11.1.3 Bristol Myers Squibb Refractory Multiple Myeloma Introduction
11.1.4 Bristol Myers Squibb Revenue in Refractory Multiple Myeloma Business (2018-2023)
11.1.5 Bristol Myers Squibb Recent Development
11.2 Teva Pharmaceutical Industries Ltd.
11.2.1 Teva Pharmaceutical Industries Ltd. Company Detail
11.2.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.2.3 Teva Pharmaceutical Industries Ltd. Refractory Multiple Myeloma Introduction
11.2.4 Teva Pharmaceutical Industries Ltd. Revenue in Refractory Multiple Myeloma Business (2018-2023)
11.2.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.3 Pfizer Inc.
11.3.1 Pfizer Inc. Company Detail
11.3.2 Pfizer Inc. Business Overview
11.3.3 Pfizer Inc. Refractory Multiple Myeloma Introduction
11.3.4 Pfizer Inc. Revenue in Refractory Multiple Myeloma Business (2018-2023)
11.3.5 Pfizer Inc. Recent Development
11.4 Janssen Global Services, LLC
11.4.1 Janssen Global Services, LLC Company Detail
11.4.2 Janssen Global Services, LLC Business Overview
11.4.3 Janssen Global Services, LLC Refractory Multiple Myeloma Introduction
11.4.4 Janssen Global Services, LLC Revenue in Refractory Multiple Myeloma Business (2018-2023)
11.4.5 Janssen Global Services, LLC Recent Development
11.5 Gilead Sciences, Inc.
11.5.1 Gilead Sciences, Inc. Company Detail
11.5.2 Gilead Sciences, Inc. Business Overview
11.5.3 Gilead Sciences, Inc. Refractory Multiple Myeloma Introduction
11.5.4 Gilead Sciences, Inc. Revenue in Refractory Multiple Myeloma Business (2018-2023)
11.5.5 Gilead Sciences, Inc. Recent Development
11.6 Fresenius Kabi
11.6.1 Fresenius Kabi Company Detail
11.6.2 Fresenius Kabi Business Overview
11.6.3 Fresenius Kabi Refractory Multiple Myeloma Introduction
11.6.4 Fresenius Kabi Revenue in Refractory Multiple Myeloma Business (2018-2023)
11.6.5 Fresenius Kabi Recent Development
11.7 GSK plc.
11.7.1 GSK plc. Company Detail
11.7.2 GSK plc. Business Overview
11.7.3 GSK plc. Refractory Multiple Myeloma Introduction
11.7.4 GSK plc. Revenue in Refractory Multiple Myeloma Business (2018-2023)
11.7.5 GSK plc. Recent Development
11.8 Novartis AG
11.8.1 Novartis AG Company Detail
11.8.2 Novartis AG Business Overview
11.8.3 Novartis AG Refractory Multiple Myeloma Introduction
11.8.4 Novartis AG Revenue in Refractory Multiple Myeloma Business (2018-2023)
11.8.5 Novartis AG Recent Development
11.9 Takeda Pharmaceutical Company Limited
11.9.1 Takeda Pharmaceutical Company Limited Company Detail
11.9.2 Takeda Pharmaceutical Company Limited Business Overview
11.9.3 Takeda Pharmaceutical Company Limited Refractory Multiple Myeloma Introduction
11.9.4 Takeda Pharmaceutical Company Limited Revenue in Refractory Multiple Myeloma Business (2018-2023)
11.9.5 Takeda Pharmaceutical Company Limited Recent Development
11.10 Genentech, Inc.
11.10.1 Genentech, Inc. Company Detail
11.10.2 Genentech, Inc. Business Overview
11.10.3 Genentech, Inc. Refractory Multiple Myeloma Introduction
11.10.4 Genentech, Inc. Revenue in Refractory Multiple Myeloma Business (2018-2023)
11.10.5 Genentech, Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Refractory Multiple Myeloma Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Proteosome Inhibitor
Table 3. Key Players of Immunomodulators
Table 4. Key Players of Anti-CD38 Monoclonal Antibody
Table 5. Key Players of Others
Table 6. Global Refractory Multiple Myeloma Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 7. Global Refractory Multiple Myeloma Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 8. Global Refractory Multiple Myeloma Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Refractory Multiple Myeloma Market Share by Region (2018-2023)
Table 10. Global Refractory Multiple Myeloma Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 11. Global Refractory Multiple Myeloma Market Share by Region (2024-2033)
Table 12. Refractory Multiple Myeloma Market Trends
Table 13. Refractory Multiple Myeloma Market Drivers
Table 14. Refractory Multiple Myeloma Market Challenges
Table 15. Refractory Multiple Myeloma Market Restraints
Table 16. Global Refractory Multiple Myeloma Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Refractory Multiple Myeloma Market Share by Players (2018-2023)
Table 18. Global Top Refractory Multiple Myeloma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Refractory Multiple Myeloma as of 2022)
Table 19. Ranking of Global Top Refractory Multiple Myeloma Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Refractory Multiple Myeloma Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Refractory Multiple Myeloma Product Solution and Service
Table 23. Date of Enter into Refractory Multiple Myeloma Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Refractory Multiple Myeloma Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Refractory Multiple Myeloma Revenue Market Share by Type (2018-2023)
Table 27. Global Refractory Multiple Myeloma Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 28. Global Refractory Multiple Myeloma Revenue Market Share by Type (2024-2033)
Table 29. Global Refractory Multiple Myeloma Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Refractory Multiple Myeloma Revenue Market Share by Application (2018-2023)
Table 31. Global Refractory Multiple Myeloma Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 32. Global Refractory Multiple Myeloma Revenue Market Share by Application (2024-2033)
Table 33. North America Refractory Multiple Myeloma Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 34. North America Refractory Multiple Myeloma Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Refractory Multiple Myeloma Market Size by Country (2024-2033) & (US$ Million)
Table 36. Europe Refractory Multiple Myeloma Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 37. Europe Refractory Multiple Myeloma Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Refractory Multiple Myeloma Market Size by Country (2024-2033) & (US$ Million)
Table 39. Asia-Pacific Refractory Multiple Myeloma Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 40. Asia-Pacific Refractory Multiple Myeloma Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Refractory Multiple Myeloma Market Size by Region (2024-2033) & (US$ Million)
Table 42. Latin America Refractory Multiple Myeloma Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 43. Latin America Refractory Multiple Myeloma Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America Refractory Multiple Myeloma Market Size by Country (2024-2033) & (US$ Million)
Table 45. Middle East & Africa Refractory Multiple Myeloma Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 46. Middle East & Africa Refractory Multiple Myeloma Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa Refractory Multiple Myeloma Market Size by Country (2024-2033) & (US$ Million)
Table 48. Bristol Myers Squibb Company Detail
Table 49. Bristol Myers Squibb Business Overview
Table 50. Bristol Myers Squibb Refractory Multiple Myeloma Product
Table 51. Bristol Myers Squibb Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 52. Bristol Myers Squibb Recent Development
Table 53. Teva Pharmaceutical Industries Ltd. Company Detail
Table 54. Teva Pharmaceutical Industries Ltd. Business Overview
Table 55. Teva Pharmaceutical Industries Ltd. Refractory Multiple Myeloma Product
Table 56. Teva Pharmaceutical Industries Ltd. Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 57. Teva Pharmaceutical Industries Ltd. Recent Development
Table 58. Pfizer Inc. Company Detail
Table 59. Pfizer Inc. Business Overview
Table 60. Pfizer Inc. Refractory Multiple Myeloma Product
Table 61. Pfizer Inc. Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 62. Pfizer Inc. Recent Development
Table 63. Janssen Global Services, LLC Company Detail
Table 64. Janssen Global Services, LLC Business Overview
Table 65. Janssen Global Services, LLC Refractory Multiple Myeloma Product
Table 66. Janssen Global Services, LLC Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 67. Janssen Global Services, LLC Recent Development
Table 68. Gilead Sciences, Inc. Company Detail
Table 69. Gilead Sciences, Inc. Business Overview
Table 70. Gilead Sciences, Inc. Refractory Multiple Myeloma Product
Table 71. Gilead Sciences, Inc. Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 72. Gilead Sciences, Inc. Recent Development
Table 73. Fresenius Kabi Company Detail
Table 74. Fresenius Kabi Business Overview
Table 75. Fresenius Kabi Refractory Multiple Myeloma Product
Table 76. Fresenius Kabi Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 77. Fresenius Kabi Recent Development
Table 78. GSK plc. Company Detail
Table 79. GSK plc. Business Overview
Table 80. GSK plc. Refractory Multiple Myeloma Product
Table 81. GSK plc. Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 82. GSK plc. Recent Development
Table 83. Novartis AG Company Detail
Table 84. Novartis AG Business Overview
Table 85. Novartis AG Refractory Multiple Myeloma Product
Table 86. Novartis AG Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 87. Novartis AG Recent Development
Table 88. Takeda Pharmaceutical Company Limited Company Detail
Table 89. Takeda Pharmaceutical Company Limited Business Overview
Table 90. Takeda Pharmaceutical Company Limited Refractory Multiple Myeloma Product
Table 91. Takeda Pharmaceutical Company Limited Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 92. Takeda Pharmaceutical Company Limited Recent Development
Table 93. Genentech, Inc. Company Detail
Table 94. Genentech, Inc. Business Overview
Table 95. Genentech, Inc. Refractory Multiple Myeloma Product
Table 96. Genentech, Inc. Revenue in Refractory Multiple Myeloma Business (2018-2023) & (US$ Million)
Table 97. Genentech, Inc. Recent Development
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Refractory Multiple Myeloma Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Refractory Multiple Myeloma Market Share by Type: 2022 VS 2033
Figure 3. Proteosome Inhibitor Features
Figure 4. Immunomodulators Features
Figure 5. Anti-CD38 Monoclonal Antibody Features
Figure 6. Others Features
Figure 7. Global Refractory Multiple Myeloma Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 8. Global Refractory Multiple Myeloma Market Share by Application: 2022 VS 2033
Figure 9. Hospital Case Studies
Figure 10. Specialty Clinic Case Studies
Figure 11. Others Case Studies
Figure 12. Refractory Multiple Myeloma Report Years Considered
Figure 13. Global Refractory Multiple Myeloma Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 14. Global Refractory Multiple Myeloma Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 15. Global Refractory Multiple Myeloma Market Share by Region: 2022 VS 2033
Figure 16. Global Refractory Multiple Myeloma Market Share by Players in 2022
Figure 17. Global Top Refractory Multiple Myeloma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Refractory Multiple Myeloma as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Refractory Multiple Myeloma Revenue in 2022
Figure 19. North America Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 20. North America Refractory Multiple Myeloma Market Share by Country (2018-2033)
Figure 21. United States Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Canada Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Europe Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Europe Refractory Multiple Myeloma Market Share by Country (2018-2033)
Figure 25. Germany Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. France Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. U.K. Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Italy Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Russia Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Nordic Countries Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Asia-Pacific Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Asia-Pacific Refractory Multiple Myeloma Market Share by Region (2018-2033)
Figure 33. China Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Japan Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. South Korea Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Southeast Asia Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. India Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Australia Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Latin America Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Latin America Refractory Multiple Myeloma Market Share by Country (2018-2033)
Figure 41. Mexico Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Brazil Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Middle East & Africa Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Middle East & Africa Refractory Multiple Myeloma Market Share by Country (2018-2033)
Figure 45. Turkey Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Saudi Arabia Refractory Multiple Myeloma Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Bristol Myers Squibb Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 48. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 49. Pfizer Inc. Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 50. Janssen Global Services, LLC Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 51. Gilead Sciences, Inc. Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 52. Fresenius Kabi Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 53. GSK plc. Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 54. Novartis AG Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 55. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 56. Genentech, Inc. Revenue Growth Rate in Refractory Multiple Myeloma Business (2018-2023)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed